CSL Limited (OTCMKTS:CSLLY – Get Free Report) saw a large decline in short interest in March. As of March 15th, there was short interest totalling 300 shares, a decline of 98.5% from the February 28th total of 20,000 shares. Approximately 0.0% of the company’s shares are short sold. Based on an average trading volume of 134,500 shares, the days-to-cover ratio is presently 0.0 days.
CSL Stock Down 2.8 %
CSL stock traded down $2.29 during midday trading on Wednesday, reaching $79.17. The stock had a trading volume of 48,223 shares, compared to its average volume of 88,004. The company has a fifty day moving average price of $82.58 and a two-hundred day moving average price of $89.83. CSL has a 12 month low of $77.37 and a 12 month high of $109.00. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.97 and a current ratio of 2.18.
Analyst Upgrades and Downgrades
Separately, The Goldman Sachs Group raised shares of CSL to a “strong-buy” rating in a research note on Thursday, January 16th.
About CSL
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.
See Also
- Five stocks we like better than CSL
- Consumer Discretionary Stocks Explained
- Energy Transfer: Powering Data With Dividends and Diversification
- What Do S&P 500 Stocks Tell Investors About the Market?
- Qualcomm Stock Is Coiling for a Breakout
- Which Wall Street Analysts are the Most Accurate?
- Is Alphabet Too Cheap to Ignore After Its Recent Correction?
Receive News & Ratings for CSL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CSL and related companies with MarketBeat.com's FREE daily email newsletter.
